At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Peginesatidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease
In Brief
A Phase 2 clinical trial evaluating Peginesatide for Anemia and 3 related conditions. Completed, enrolled 22 participants across 4 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the ability of peginesatide (AF37702) to increase and maintain increased hemoglobin levels in participants with chronic kidney disease (CKD) (either not on dialysis, receiving regular hemodialysis or peritoneal dialysis, or following renal transplant) with confirmed antibody-mediated pure red cell aplasia (PRCA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedApr 2006
Primary CompletionOct 2016
Study CompletionOct 2016
TodayJul 2026
First PostedApr 17, 2006
Enrollment StartApr 6, 2006
Primary CompletionOct 24, 2016
Study CompletionOct 31, 2016
TodayJul 2, 2026
Enrollment to primary: 10.5 yearsPosted 20.2 years ago
Interventions
Peginesatidedrug
Peginesatide injection